PT  - JOURNAL ARTICLE
AU  - Kerstjens, Huib A.M.
AU  - Van Zyl-Smit, Richard
AU  - Chapman, Kenneth
AU  - Maspero, Jorge
AU  - Hosoe, Motoi
AU  - Tanase, Ana-Maria
AU  - Lawrence, David
AU  - Pethe, Abhijit
AU  - Shu, Xu
AU  - Mezzi, Karen
AU  - D'Andrea, Peter
TI  - Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus fluticasone/salmeterol (FLU/SAL) in ex-smoker and never smoker patients with inadequately controlled asthma: Post hoc analysis of IRIDIUM study
AID  - 10.1183/13993003.congress-2021.PA3387
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA3387
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/PA3387.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/PA3387.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Introduction: Smoking increases inflammation and contributes to lung function decline with detrimental effects on asthma control. IRIDIUM study established clinical benefit of MF/IND/GLY vs FLU/SAL in patients with inadequately controlled asthma. We evaluated the effect of once-daily medium- (80/150/50µg) and high-dose MF/IND/GLY (160/150/50µg) vs twice-daily high-dose FLU/SAL (500/50µg) in ex- and never smokers.Methods: IRIDIUM (NCT02571777), a 52-wk, randomised, double-blind, double-dummy study included patients with symptomatic asthma (ACQ-7≥1.5), ≥1 exacerbation in previous year, FEV1 <80% and not current smokers. Trough FEV1 at wk 26 (primary end point) and exacerbations over 52 wks were evaluated by smoking history at screening.Results: ~80% patients were non-smokers; ~20% ex-smokers. Both doses of MF/IND/GLY showed greater improvements in trough FEV1 vs high-dose FLU/SAL, independent of smoking status (Figure 1A). There were trends for greater reduction in exacerbations with both doses of MF/IND/GLY vs high-dose FLU/SAL, with no clear difference dependent on smoking pattern (Figure 1B).Conclusion: Both doses of MF/IND/GLY showed benefit in lung function and asthma exacerbations vs high-dose FLU/SAL independent of smoking history, indicating no effect of smoking history on efficacy of MF/IND/GLY. FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3387.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).